Tag: antidepressants

Articles

• ER+/PR- breast cancer characteristics

News

04/25/15

Use of SSRI antidepressants linked to small increase in BC risk

Studies

• The application of antidepressant drugs in cancer treatment Cite
  Zheng Y, Chang X, Huang Y, He D. The application of antidepressant drugs in cancer treatment. Biomedicine & Pharmacotherapy. Elsevier BV; 2023; 157:113985 10.1016/j.biopha.2022.113985
• Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models Cite
  Schneider MA, Heeb L, Beffinger MM, Pantelyushin S, Linecker M, Roth L, et al. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science Translational Medicine. American Association for the Advancement of Science (AAAS); 2021; 13 10.1126/scitranslmed.abc8188
• Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review Cite
  Bradbury M, Hutton B, Beltran-Bless A, AlZahrani M, Lariviere T, Fernandes R, et al. Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.10.003
• Implications of Antidepressants Use in Breast Cancer: A Brief Review Cite
  Strazzanti A, Martorana F, Intagliata E, Lanzafame K, Pavone G, Mauro S, et al. Implications of Antidepressants Use in Breast Cancer: A Brief Review. Surgery, Gastroenterology and Oncology. Celsius Publishing House; 2020; 25:229 10.21614/sgo-25-5-229
• Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines Cite
  Stapel B, Melzer C, von der Ohe J, Hillemanns P, Bleich S, Kahl KG, et al. Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-020-80850-9
• The association between antidepressants use and development of cognitive impairment among older women diagnosed with breast cancer Cite
  Alatawi Y, Hansen RA, Chou C, Qian J, Suppiramaniam V, Cao G. The association between antidepressants use and development of cognitive impairment among older women diagnosed with breast cancer. European Geriatric Medicine. Springer Science and Business Media LLC; 2020; 11:1017-1026 10.1007/s41999-020-00349-4
• Depression, Antidepressant Use, and Breast Cancer Risk in Pre- and Postmenopausal Women: A Prospective Cohort Study Cite
  Reeves KW, Okereke OI, Qian J, Tamimi RM, Eliassen AH, Hankinson SE. Depression, Antidepressant Use, and Breast Cancer Risk in Pre- and Postmenopausal Women: A Prospective Cohort Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 27:306-314 10.1158/1055-9965.epi-17-0707
• Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study Cite
  Donneyong MM, Bykov K, Bosco-Levy P, Dong Y, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. BMJ; 2016;:i5014 10.1136/bmj.i5014
• Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors Cite
  Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, et al. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv337 10.1093/jnci/djv337
• Breast cancer recurrence in relation to antidepressant use Cite
  Chubak J, Bowles EJA, Yu O, Buist DSM, Fujii M, Boudreau DM. Breast cancer recurrence in relation to antidepressant use. Cancer Causes & Control. Springer Science and Business Media LLC; 2015; 27:125-136 10.1007/s10552-015-0689-y
• How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years? Cite
  Dieudonné AS, De Nys K, Casteels M, Wildiers H, Neven P. How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?. Acta Clinica Belgica. Informa UK Limited; 2014; 69:47-52 10.1179/0001551213z.00000000017
• Anti-depressant therapy and cancer risk: A nested case-control study Cite
  Boursi B, Lurie I, Mamtani R, Haynes K, Yang Y. Anti-depressant therapy and cancer risk: A nested case-control study. European Neuropsychopharmacology. Elsevier BV; 2015; 25:1147-1157 10.1016/j.euroneuro.2015.04.010
• Depression and Antidepressant Use in Relation to Breast Cancer Risk in the Nurses Health Study Cite
  Reeves K, Okereke O, Qian J, Hankinson S. Depression and Antidepressant Use in Relation to Breast Cancer Risk in the Nurses Health Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2015; 24:761.3-762 10.1158/1055-9965.epi-15-0107
• The Antidepressant Desipramine and α2-Adrenergic Receptor Activation Promote Breast Tumor Progression in Association with Altered Collagen Structure Cite
  Szpunar MJ, Burke KA, Dawes RP, Brown EB, Madden KS. The Antidepressant Desipramine and α2-Adrenergic Receptor Activation Promote Breast Tumor Progression in Association with Altered Collagen Structure. Cancer Prevention Research. American Association for Cancer Research (AACR); 2013; 6:1262-1272 10.1158/1940-6207.capr-13-0079
• Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations Cite
  L’Espérance S, Frenette S, Dionne A, Dionne J. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Supportive Care in Cancer. Springer Science and Business Media LLC; 2013; 21:1461-1474 10.1007/s00520-013-1732-8
• Use of antidepressants and the risk of breast cancer: a meta-analysis Cite
  Eom C, Park SM, Cho K. Use of antidepressants and the risk of breast cancer: a meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:635-645 10.1007/s10549-012-2307-y
• CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application Cite
  van der Merwe N, Bouwens CSH, Pienaar R, van der Merwe L, Yako YY, Geiger DH, et al. CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application. Metabolic Brain Disease. Springer Science and Business Media LLC; 2012; 27:319-326 10.1007/s11011-012-9312-z
• Coprescription of Tamoxifen and Medications That Inhibit CYP2D6 Cite
  Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, et al. Coprescription of Tamoxifen and Medications That Inhibit CYP2D6. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:2768-2776 10.1200/jco.2009.23.8931
• Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study Cite
  Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. BMJ; 2010; 340:c693-c693 10.1136/bmj.c693
• Antidepressant use and breast cancer risk Cite
  Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2005; 95:131-140 10.1007/s10549-005-9056-0
• Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival Cite
  Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Research. Springer Science and Business Media LLC; 2009; 11 10.1186/bcr2448